

2023
KOREA
INTERCHANGE
SEOUL | 11-14 DECEMBER



#### State of the Consortium

David A. Evans President and CEO, CDISC 2023 Korea Interchange



# Meet the Speaker

Dave Evans

Title: President and CEO

Organization: CDISC

Dave Evans is recognized industry-wide as a leading technology visionary for developing and implementing complex process and system solutions and as an expert in the areas of information standards, regulatory compliance and quality governance. He was the architect and developer of the first electronic drug submission to the FDA in 1985 and has been responsible for more than 100 electronic regulatory submissions and complex clinical data warehouse systems. He brings over 40 years' experience to CDISC, serving in various executive-level positions in software development, clinical research, regulatory and healthcare industries. Most recently, he was the Global Head of Quality Governance and Regulatory Compliance for Accenture Life Sciences. Prior to that, he was CIO of Octagon Research Solutions. He has also served on the CDISC Board and has chaired the CAC.

Dave received his MS in Biomedical Engineering from Drexel University and his BS in Biology from Ursinus College.

# FROM YESTERYEAR TO TODAY

So what is true for life itself is no less true for the universe: knowing where you came from is no less important than knowing where you are going.

- Neil deGrasse Tyson

Think of these things, whence you came, where you are going, and to whom you must account.

- Benjamin Franklin



# EARLY CDISC History - 1997 - 2000

#### 1997

- Founding Members
  - Tom Tunstall, Bron Kisler, Becky Kush
- Two volunteer Groups
  - Nomenclature and Modeling
- 'CDISC' was Named

#### 1998

- Nomenclature became Glossary Group
- Modeling held numerous meetings



# **EARLY CDISC History (continued)**

#### 1999

- CDISC Volunteers offered assistance to incorporate nonprofit organization
- Split Modeling Group into two teams
  - Submission (SDS)
  - Data
  - Acquisition (DAS→ODM)

#### 2020

CDISC is launched!



# **CDISC** Is Officially Launched!



- February 2000 Business Case Presented
- June 2000 Charter Members
- **June 2000 –** Funding = \$40,000
- One first full-time employee hired
- Rebecca Kush, President



## **CDISC Obtained Non-Profit Status**



#### 2000

CDISC registered as 501(c)(6) non-profit organization

#### 2011

Status changed from 501(c)(6) to 501(c)(3) non-profit organization



# **CDISC Interchanges**

First CDISC Interchanges held in the following countries:

- Europe 2003 in Dublin
- Japan 2003 in Tokyo
- USA 2003 in Bethesda
- China 2007 in Shanghai
- Korea 2023 in Seoul





## **REGULATORS MANDATE**





- FDA published Guidance on Standards Study Data in 2014 all studies submitted in 2016 <u>all studies that start in the year</u> 2017 or later will be required to submit their data to the FDA in an electronic format i.e. CDISC.
- PMDA followed suit sharing timeline for implementation of electronic data submission using CDISC Standards in 2016



## UPDATE!!!



October 2019 – NMPA ('National Medical Products Administration, new name for China FDA) recommended use of CDISC Standards – SDTM and ADaM for submission



## **How Far We have Come**

#### Standards

• From Foundational Standards to 49 Therapeutic Area Standards

## Training

 We started out with Public training, now we have Virtual training, Public and Private training, On-Demand Online training, in addition to webinars, workshops, licensed trainer instruction and more

## Membership

• 18 Members in 2000, today we have over 500

#### Revenue

• \$40,000 in 2000 to over \$11,000,000 in 2023

## Employees

• 1.5 in 2000 to over 40 today



## CDISC LOGOS THROUGH THE YEARS









# cdisc - Who we are today

**Mission**: To develop and support global, platform-independent data standards that enable information system interoperability to improve medical research and related areas of healthcare

- Global Non-profit Consensus-based Standards Development Organization
- 20+ Years of Regulatory Clinical Data Standards Development and Implementation
- Experienced Leadership Team and Dedicated Staff of 40+ Professionals and SMEs
- Volunteer Network of 1000+ Industry Experts
- 530+ Member Organizations
- Widely Adopted and Freely Available Clinical Research Data Standards
- Mature and Globally Accepted Standard Governance Processes
- Innovative Open-Source Technology for Standards Library and Metadata Management
- Involved in a wide range of emerging Industry Initiatives and Projects
- Collaborative Ecosystem of Relationships and Partnerships
  - Members, Regulators, Patient Foundations, Academia, SDOs and Industry



## **Alliances and Collaborations**

#### **CFAST & Therapeutic Area Partnerships**

CDISC collaborates with many organizations to develop Therapeutic Area (TA) standards for multiple disease areas through the Coalition for Accelerating Standards and Therapies (CFAST) initiative, as well as other partnerships.





#### **Regulatory Collaborations**

CDISC works closely with regulators around the world to ensure that CDISC standards will 1) streamline research from protocol/study design and trial registration through analysis and reporting; 2) facilitate the eSubmission review process; 3) ensure that clinical research is high quality; and 4) support the approvals of safe and efficacious medicines for patients.

Regulators also contribute to TA standards development









International
Organization for
Standardization


















SCIENCE MEDICINES HEALTH





CDISC collaborates with other SDOs to develop standards that are synergistic to support a learning health system based upon high quality research.





CDISC and PhUSE partner to further the mission of each organization collectively, with CDISC focusing on the development of global, platform-independent data standards, and PhUSE focusing on the implementation and use of the CDISC standards. The two organizations work to combine efforts on key initiatives around end-to-end standards. The standards and semantics, strengthening an interdependent process.








# **CDISC Members = Global Community**

#### Members by Industry



#### Members by Location





## **CDISC Members Around the Globe**





## **CDISC Members**





.......

. . . . . . 6

. . . . . . . 6

# CDISC COORDINATING COMMITTEES (3C)

Five CDISC Coordinating Committees in 2023:

- CDISC Europe (E3C) in 2001
- CDISC Japan (J3C) in 2002
- CDISC China (C3C) in 2007
- CDISC Korea (K3C) in 2017
- CDISC TMF (T3C) in 2023



# CDISC KOREA COORDINATION COMMITTEE (K3C)

Organization Type	Organization Name	Member Name
Academic	DCUMC(Daegu Catholic University Medical Center)	Im-Hee Shin, Ph.D.(Maria)
		Sang-Gyu Kwak, Ph.D.
Academic	Dongguk University	Eon-Ho Kim, Ph.D.
		Hyun-Moon Kim
CRO(Non-clinical)	Biotoxtech, Inc.	Cheol-Beom Park, M.D.
CRO(Clinical)	LSK Global Pharma Services	Byeong-Kwan Park, Ph.D.
CRO(Clinical)	Symyoo, Inc.	Dong-Jin Yoo, M.D.
Government	Korea Institute Toxicology	Yong-Beom Kim, Ph.D
Pharmaceutical Company	Daewoong Pharmaceutical Co. Ltd.	Jee-Sun Lee, M.D, Ph.D.
Pharmaceutical Company	SK Chemicals	Hyun-Soo Lee
Technical Service Provider	Clupea, Inc.	Dong-Hoon Cho, Ph.D.
		Gi-Hwan Kim
Technical Service Provider	SAS Korea JMP	Chul-Hee Min



# **ROLE OF A 3C**





# **Summary of Main Responsibilities of 3C**

#### CDISC Standards

Promote and advocate the use of CDISC Standards

#### CDISC Events

Assist CDISC Events Team in organizing and promoting CDISC Interchanges

#### Training

Host/promote CDISC training and seminars

#### Translation

Help with translation of CDISC Standards and Training materials

#### Communication

- Provide update CDISC on activities
- Support communication with Regulators



# **Announcing 2024 CDISC Interchanges**









# Thank You to Our Korea Interchange Sponsors

Diamond

Diamond

Ruby

Sapphire









#### **Exhibitors**













# **Thank You to the Organizing Team**

#### **CDISC TEAM**

- Bernard Klinke
- Sheila Leaman
- Pearce O'Neal
- Andrea Vadakin

#### **KOREATEAM**

- Dr. Im Hee Shin
- Gihwan Kim
- Jamie Kim



## What is the next stage on the Clinical Information Journey?

CDISC has always been an evolving transformational standards organization for information used in clinical research and regulatory submission.


## CDISC Data Standards Lifecycle




#### Automation requires:


- Standard Machine-executable content for Useability
- Standard Technology Interfaces for Integration for Accessibility
- Standard Verification and Conformance Rules for Integrity
- Standard Trial Design Specifications for Total Automation of the Digital Data Flow





















# Digital Data Flow (DDF) Initiative


Write Once, Read Many






# Digital Data Flow (DDF) Initiative

Write Once, Read Many







## M11 Is ...

#### ICH CLINICAL ELECTRONIC STRUCTURED HARMONISED PROTOCOL (CeSHarP)

#### https://www.ich.org/page/multidisciplinary-guidelines



INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE

ICH HARMONISED GUIDELINE

CLINICAL ELECTRONIC STRUCTURED HARMONISED
PROTOCOL
(CESHARP)

M11

Draft version

Endorsed on 27 September 2022

Currently under public consultation

At Step 2 of the ICH Process, a consensus draft text or guideline, agreed by the appropriate ICH Expert Working Group, is transmitted by the ICH Assembly to the regulatory authorities of the ICH regions for internal and external consultation, according to national or regional procedures.

Provides background, purpose, and scope as a guideline



INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE

ICH HARMONISED GUIDELINE

CLINICAL ELECTRONIC STRUCTURED HARMONISED PROTOCOL (CESHARP)

M11 TEMPLATE

Draft version

Endorsed on 27 September 2022

Currently under public consultation

At Step 2 of the ICH Process, a consensus draft text or guideline, agreed by the appropriate ICH Expert Working Group, is transmitted by the ICH Assembly to the regulatory authorities of the ICH regions for internal and external consultation, according to national or regional procedures.

Provides the written format for the Interventional Clinical Trial Protocol Template



INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE

ICH HARMONISED GUIDELINE

CLINICAL ELECTRONIC STRUCTURED HARMONISED
PROTOCOL
(CESHARP)

M11 TECHNICAL SPECIFICATION

Draft version

Endorsed on 27 September 2022

Currently under public consultation

At Step 2 of the ICH Process, a consensus draft text or guideline, agreed by the appropriate ICH Expert Working Group, is transmitted by the ICH Assembly to the regulatory authorities of the ICH regions for internal and external consultation, according to national or regional procedures.

Provides the technical representation aligned with the guideline and protocol template



# **Template for Description of Trial Design**

#### 4.1 Description of Trial Design

Describe the trial intervention model (for example, single group, parallel group, cross-over, factorial, sequential), the expected number of participants, and the control method (for example, placebo, active comparator, low dose, historical, standard of care, sham procedure, or none [uncontrolled]).

If applicable, indicate the type of trial (for example, superiority, non-inferiority, dose escalation, or equivalence).




# **Technical Specification for Description of Trial Design**



- Variables
- Concept/Terminology
- Code lists
- Conformance




#### **CDISC M2/M11 Engagement**






#### The Clinical Trial Information Flow



### The Clinical Trial Information Flow




cdisc

#### The Clinical Trial Information Flow




#### The Clinical Trial Information Flow cdisc **Local Registration and Approval CH M11** (ClinicalTrials.gov, EuDRA CT, ANMAT, ReNIS, REBEC, **DHTs** REPEC, KRPIA, CTRI, NMRR, RNEC, PHRR, etc.) **FDA** cdisc cdisc **EMA** Clinical **PRM** USDM **PMDA** Development ΓMF Plan 6 CTMS, eTMF, RIM **SDTM** Clinical Study Study Design Report Metadata Statistical cdisc cdisc Analysis Plan Statistical Define-XMI **SEND** Core Analysis Clinical METADATA EXCHANGE cdisc ab services **Endpoints ADaM** eLearning **Systems** cdisc cdisc Analysis cdisc **BCs IWRS, IVRS ARS** Results cdisc & TLFs CONTROLLED Study Ref Data **Standards** cdisc cdisc cdisc **ODM eCRF CDASH** cdisc

# **CDISC Library Provides the Foundation**



## **CDISC Library Provides the Foundation**






Dave Evans – President & CEO, CDISC devans@cdisc.org













# 감사합니다!

